These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19922077)

  • 1. Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature.
    Minces LR; Ho KS; Veldkamp PJ; Clancy CJ
    Scand J Infect Dis; 2009; 41(11-12):892-7. PubMed ID: 19922077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
    Jandourek A; Brown P; Vazquez JA
    Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
    [No Abstract]   [Full Text] [Related]  

  • 4. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review.
    Angel-Moreno A; Boronat M; Bolaños M; Carrillo A; González S; Pérez Arellano JL
    J Infect; 2005 Oct; 51(3):e85-7. PubMed ID: 16230210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
    Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
    J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter-related fungemia caused by Candida intermedia.
    Ruan SY; Chien JY; Hou YC; Hsueh PR
    Int J Infect Dis; 2010 Feb; 14(2):e147-9. PubMed ID: 19497773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
    Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
    J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida glabrata fungaemia in intensive care units.
    Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal candidaemia in Kuwait: a 12-year study of risk factors, species spectrum and antifungal susceptibility.
    Al-Sweih N; Khan Z; Khan S; Devarajan LV
    Mycoses; 2009 Nov; 52(6):518-23. PubMed ID: 18983425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
    Colombo AL
    Braz J Infect Dis; 2000 Jun; 4(3):113-8. PubMed ID: 10934493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
    Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
    Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
    Clancy CJ; Staley B; Nguyen MH
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Candida albicans fungemia with pulmonary localization treated with fluconazole. A case report].
    Thomas F; Mebtouche B; Clavier H; Kalfon P
    Rev Pneumol Clin; 2000 Feb; 56(1):37-40. PubMed ID: 10740113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and outcome for nosocomial breakthrough candidaemia.
    Pasqualotto AC; Nedel WL; Machado TS; Severo LC
    J Infect; 2006 Mar; 52(3):216-22. PubMed ID: 15936825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
    Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use.
    Hope W; Morton A; Eisen DP
    J Hosp Infect; 2002 Jan; 50(1):56-65. PubMed ID: 11825053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical aspects and prognosis of candidemia, a 6-year retrospective study].
    Bregenzer T; Evison-Eckstein AC; Frei R; Zimmerli W
    Schweiz Med Wochenschr; 1996 Oct; 126(43):1829-33. PubMed ID: 9005522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients.
    Giusiano G; Mangiaterra M; Garcia Saito V; Rojas F; Gómez V; Díaz MC
    Chemotherapy; 2006; 52(5):254-9. PubMed ID: 16899974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triazole-resistant candidaemia following posaconazole exposure.
    Weiler S; Lass-Flörl C; Auberger J; Bellmann-Weiler R; Stein M; Joannidis M; Bellmann R
    Int J Antimicrob Agents; 2009 May; 33(5):494-5. PubMed ID: 19153033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.